Heska Corporation (HSKA)
(Delayed Data from NSDQ)
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Jazz Pharma Completes NDA Filing for Leukemia Drug to FDA
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) recently announced that it has completed the rolling submission of a new drug application (NDA) to the FDA, seeking approval for its leukemia candidate, Vyxeos.
Zacks.com featured highlights: Heska, Quidel, Trinseo S.A., Advanced Energy Industries and Pioneer Natural Resources
by Zacks Equity Research
Zacks.com featured highlights: Heska, Quidel, Trinseo S.A., Advanced Energy Industries and Pioneer Natural Resources
Bayer Announced Positive Data for Cancer Drug Copanlisib
by Zacks Equity Research
Bayer Aktiengesellschaft (BAYRY) announced positive data on its experimental candidate copanlisib.
GlaxoSmithKline Initiates Phase III Study with Mepolizumab
by Zacks Equity Research
GlaxoSmithKline plc (GSK) announced the initiation of a phase III study with Nucala (mepolizumab,) in patients with severe hypereosinophilic syndrome (HES).
BioDelivery to Grant New Patents for its Marketed Drugs
by Zacks Equity Research
BioDelivery Sciences (BDSI) recently announced its decision to grant two new patents to extend the patent life for all three of its marketed products, Belbuca , Bunavail, and Onsolis.
5 Stocks with Solid Efficiency Ratio to Buy in April
by Tirthankar Chakraborty
Efficiency level is often considered to be an important parameter to find out whether a company has the potential to rake in handsome returns.
Spectrum (SPPI) Initiates Phase II Study for Cancer Candidate
by Zacks Equity Research
Spectrum Pharmaceuticals (SPPI) recently announced that it has initiated a phase II trial to evaluate its pipeline candidate, poziotinib for the treatment of non-small cell lung cancer patients.
Roche's Rituxan Gets FDA Advisory Committee's Recommendation
by Zacks Equity Research
Roche Holding AG's (RHHBY) member, Genentech announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of subcutaneous Rituxan /hyaluronidase for the treatment of patients with certain blood cancers.
Bill Ackman Apologizes for Valeant Investment Error
by Zacks Equity Research
In a letter addressed to shareholders, Bill Ackman, chairman of Perishing Square Holdings, Ltd stated that investing in Valeant Pharmaceuticals (VRX) was a big mistake on his part.
Acorda Presents Data for Parkinson's Candidate CVT-301
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) announced results from two ongoing, long-term safety studies of CVT-301 in patients suffering with Parkinson's disease.
Amgen's Leukemia Drug Accepted for Priority Review by FDA
by Zacks Equity Research
Amgen Inc. (AMGN) recently announced that its supplemental biologics license application (sBLA) for its leukemia immunotherapy, Blincyto, has been accepted for priority review by the FDA.
Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis.
Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage
by Zacks Equity Research
Shares of Athersys, Inc. (ATHX) surged significantly in the post market trading on Mar 28 after research firm William Blair initiated a coverage on the stock with an outperform rating.
Corcept (CORT) Strives to Commercialize Key Drug Korlym
by Zacks Equity Research
We issued an updated report on Corcept Therapeutics Incorporated (CORT) on Mar 28.
Vertex Combo Data on Kalydeco+VX-661 Positive in Phase III
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) announced positive data from two phase III studies evaluating its lead marketed drug Kalydeco (ivacaftor) in combination with tezacaftor VX-661 (tezacaftor) in patients suffering from cystic fibrosis.
Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y
by Zacks Equity Research
Orexigen Therapeutics, Inc.???s (OREX) loss of $2.67 per share in the fourth quarter of 2016, significantly wider than the both Zacks Consensus Estimate of a loss of 54 cents and the year-ago loss of $1.20.
Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).
Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula
by Zacks Equity Research
TESARO, Inc. (TSRO) recently announced that the FDA has approved its oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor Zejula for ovarian cancer in women.
Will Endo's Troubles Continue to Dent Performance in 2017?
by Zacks Equity Research
2017 will continue to challenging for Endo Pharmaceuticals (ENDP) as the generics base business and the legacy branded pain franchise are expected to decline further.
Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion
by Zacks Equity Research
Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.
Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults.
Why Heska Corporation (HSKA) Could Be an Impressive Growth Stock
by Zacks Equity Research
Heska Corporation (HSKA) stock has a double digit earnings growth prospect and an impressive Zacks Rank that might bring to the analysts better days ahead for HSKA
Merrimack (MACK) Starts Enrollment in Solid Tumors Study
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) announced that it has enrolled the first patient in a phase I study on MM-310 for solid tumors.
Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA
by Zacks Equity Research
Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.
Shire (SHPG) Rare Disease Drug Gets Fast Track Designation
by Zacks Equity Research
Shire plc (SHPG) announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).